Research programme: ocular therapeutics - Benitec Biopharma

Drug Profile

Research programme: ocular therapeutics - Benitec Biopharma

Alternative Names: BB 201; BB 202; BB AMD 211; BB AMD 231; TT 211; TT 231

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator Tacere Therapeutics
  • Developer Benitec Biopharma
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Wet age-related macular degeneration

Most Recent Events

  • 13 Oct 2016 Preclinical trials in Wet age-related macular degeneration in USA (IV), before October 2016 (Benitec Biopharma pipeline, October 2016)
  • 12 Oct 2016 Benitec Biopharma plans to file an IND application with the US FDA in USA for Age-related macular degeneration in 2017 (Benitec Biopharma Pipeline, October 2016)
  • 12 Oct 2016 Benitec Biopharma plans a phase I/IIa trial for Age-related macular degeneration (Benitec Biopharma Pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top